EM
No verificado

EMD Serono

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud
24/11/2025
Biotecnología
Higiene alimentaria
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Industria
EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
1.00
17/10/2025
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Industria
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
1.00
16/10/2025
Sanidad
Ciencia
Farmacéutica
Política Nacional
Biotecnología
Higiene alimentaria
Salud
Mercado laboral
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
1.00
17/09/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Análisis de Mercados
Industria
EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
1.00
12/06/2025
Biotecnología
Técnica
Salud
Sanidad
Farmacéutica
Tecnología
Ciencia
Medicina - Varios
Eventos
Industria
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
1.00
28/05/2025
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Industria
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
1.00
22/05/2025
Eventos
Industria
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
1.00
10/12/2024
Multimedia
Oncología
Salud
Sanidad
Farmacéutica
Biotecnología
Mercado laboral
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
1.00
12/11/2024
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Industria
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0